Navigation Links
New lymphoma therapies targets diverse and difficult cancer
Date:4/24/2008

NEW YORK (April 24, 2008) -- The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

While all lymphoma types can be cured or managed as a chronic disease, its complexity and variation do not allow for a one-size-fits-all treatment approach. Instead, it necessitates highly specialized and individualized approaches.

With a dozen new therapies in development -- one of the largest portfolios of lymphoma drugs under development anywhere -- the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center is meeting this challenge with highly effective new treatments for the disease, giving hope to the more than one million lymphoma patients worldwide.

In 2006, NewYork-Presbyterian/Columbia recruited Dr. Owen A. O'Connor, one of the world's top lymphoma researchers, to lead its Lymphoid Development and Malignancy Program, and direct more than 25 full-time scientists and physician scientists.

"By increasing the number and quality of treatment options for lymphoma patients, we are improving their chances for survival. This is especially critical for patients who haven't responded to standard therapies," says Dr. O'Connor, who is also chief of the Lymphoma Service at NewYork-Presbyterian/Columbia and associate professor of medicine at Columbia University College of Physicians and Surgeons.

One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is PDX (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, which allows it to be absorbed by the tumor, wher
'/>"/>

Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. January 1 Looms Large for Lymphoma Patients
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Possible Cure for Rare Lymphoma Reported
7. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
9. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
10. Lymphoma drug used to treat skin disorders
11. Firefly genes allow testing of new therapy against lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ospital Ship Serving in West Africa Receives Acces...ley, Texas October 6, 2008 -- www.seamobile.com [S... of communications services to remote locations, a...oxNews channel via satellite to Mercy Ships onboar... The Africa Mercy is the world,s largest non-gove...
(Date:10/5/2008)...iderable disparities in survival related to race a...and neck cancer. Published in the November 15, 200...e American Cancer Society, the study indicates tha...t could improve outcomes for these cancers among A...dies have examined disparities in cancer survival ...
(Date:10/5/2008)...ifficult to kill a spider as it scurries across th...er set foot on a plane. While nothing physically ...r can keep them from the task at hand. , The sam...hysical activity, according to research presented ... , Researchers from the Center for Obesity Resea...
(Date:10/3/2008)...ide Komen Community Challenge Campaign to Close,th...come Women and Women of ... Pennsylvania House Speaker Dennis,O,Brien (R-169t... survivors,and advocates from the Philadelphia Aff...ic forum this morning to call for policies to clos...
Breaking Medicine News(10 mins):Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 3
... obesity rates are soaring as well.Studies say tha...e world by the end of the decade and raise the ris...010 the number of overweight and obese youngsters ...ould be 26 million. Over a million children will ...
...wn are growing in number, and this has led to a no...40’s desirous of having a child are going to be gi...th Service.// Hospital administration is re-worki...ren without their partners. Camden primary care tr...
...nternational, two major pharma companies, agreed t...d flu that will cater to the needs of Indian and S...harat Biotech will fund all pre-clinical and clini... responsible for the commercialisation of the sing...
...tyle like regular exercise and nutritious diet can... other researchers at John Hopkins// Bloomberg Sch... erectile dysfunction (ED) from more than 2,200 ad...as collected from participants in the US governmen...
Other Medicine News:Health News:Pharma Companies Tie Up To Develop Bird Flu Vaccine 2
(Date:10/6/2008)... - Data Presented at ACG Annual Scientific Confer...nwood Pharmaceuticals,(formerly Microbia) today an...nical studies delineating the role that cyclic gua...ntestinal pain. These studies,demonstrate that cGM...of,intestinal hyperalgesia and desensitizes coloni...
(Date:10/6/2008)...lts from Phase 3b Studies with Durezol Dosed Prior...Sirion Therapeutics, Inc., a,privately held ophtha...today that Durezol(TM) (difluprednate ophthalmic e...zol, which was approved by the U.S. Food and,Drug ...ic corticosteroid,indicated for the treatment of i...
(Date:10/6/2008)...than 60 percent of moderate to severe patients ach... achieved endoscopic remission at Week 10,in data ...merican College,of Gastroenterology (ACG) Annual S...ire/ -- UCB today presented data from a,large, pro...t in Crohn,s,disease (CD) with a biologic compound...
(Date:10/6/2008)...LE, Oct. 6 /- Dendreon Corp... today, Monday, October 6, 2008 at 9:00 AM,ET (6:0...ysis of its IMPACT,(IMmunotherapy for Prostate Ade...cal trial of PROVENGE(R) (sipuleucel-T), the Compa... for the treatment of advanced prostate,cancer., ...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 1Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 1Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 1TopoTarget Successfully Buys Back Full Control of Belinostat 4752 2TopoTarget Successfully Buys Back Full Control of Belinostat 4752 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 4TopoTarget Successfully Buys Back Full Control of Belinostat 4752 5TopoTarget Successfully Buys Back Full Control of Belinostat 4752 6TopoTarget Successfully Buys Back Full Control of Belinostat 4752 7Mannatech Launches Business in South Africa 17387 1Mannatech Launches Business in South Africa 17387 2Mannatech Launches Business in South Africa 17387 3
...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products: